Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer expands pipeline candidates

Pfizer expands pipeline candidates

3rd April 2009

Pfizer is expanding the alignment of its pipeline candidates to help meet the needs of healthcare professionals and patients worldwide, it has asserted.

Within the last six months, the research-based pharmaceutical company has started seven phase III clinical trials, which includes two new studies it announced this week.

One examination ? which was a result of a successful phase II study – is of a first-in-class JAK inhibitor (CP-690,550). This is an orally-administered, disease-modifying antirheumatic drug.

Ian Read, president of the company’s worldwide pharmaceutical operations, asserted the firm is committed to bringing new and effective therapies to sufferers in areas where medical needs are unmet.

“Our new business unit structure will enable us to advance our development programmes with urgency and efficiency in support of achieving our regulatory submission goal and providing high value therapies,” he commented.

Earlier this week, Pfizer released data from a study that found 47 per cent of smokers with a history of cardiovascular disease were able to quit smoking for a longer period of time if they took Chantix/Champix.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.